How vaccine maker Dynavax tested itself and found a corporate cure

The company brought in $900 million selling its immune-stimulating adjuvant to others seeking Covid vaccines. Now it’s turning that cash into a pipeline of potential vaccines against shingles, plague and more.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks